BMS-986020 is primarily investigated for its potential therapeutic applications in treating fibrotic diseases, particularly idiopathic pulmonary fibrosis (IPF). It functions as a lysophosphatidic acid receptor 1 (LPA1) antagonist, which plays a key role in the pathogenesis of fibrosis by promoting fibroblast recruitment and activation. By inhibiting LPA1, BMS-986020 aims to reduce the progression of fibrosis, improve lung function, and enhance the quality of life for patients with IPF. Clinical trials have explored its efficacy and safety, positioning it as a promising candidate for addressing unmet medical needs in fibrotic disorders.